DRUG · Unmapped registry intervention
CD19-BCMA CAR-T cells infusion
Find medicine records ·
Find other trials using this name
Clinical trial
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedCD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Beijing GoBroad Hospitallead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06947460 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.